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The global increase in bacterial resistance to antibiotics has resulted 
in a tipping point towards a post-antibiotic era, where common 
infections that were previously easily treated now require anti-
biotics of last resort or are de facto untreatable.[1-3] South Africa 
(SA) has seen an alarming increase in rates of extended-spectrum 
beta-lactamase (ESBL)-producing Gram-negative bacteria[4-5] and 
carbapenem-resistant Enterobacteriaceae (CRE), which have been 
reported from every province.[6] The main driver of antibiotic resis-
tance is overuse and misuse of antibiotics.[7-9] Poor infection pre-
vention practice in healthcare settings fuels the spread of resistant 
bacteria, which cause healthcare-associated infections in SA and 
abroad.[10,11] Antibiotic stewardship programmes (ASPs),[3,12] which 
aim to optimise the use of antibiotics, combine targeted interven-
tions with surveillance, guidelines, education, and monitoring and 
evaluation through audit.[13] In 2012, we reported the results of a 
pilot ASP at Groote Schuur Hospital, Cape Town, which showed for 
the first time that antibiotic stewardship (AS) could be successfully 
introduced into the SA public sector.[14]
In this article, we demonstrate that when rolled out on a greater 
scale this programme can deliver sustained reductions in antibiotic 
consumption, and achieve cost-savings within 4 years that could pay 
for the programme itself.
Methods
Setting
Groote Schuur Hospital, the 945-bed tertiary academic teaching 
hospital of the University of Cape Town, offers medical, surgical, 
obstetric, psychiatric and emergency care to Cape Town’s Metro West 
population. Four wards are dedicated to long-stay (>48 hours) acute 
general internal medicine admissions, and consultant-led antibiotic 
prescribing is the norm.
AS intervention
The activities of the ASP have been presented previously in 
2012.[14] Briefly, we instituted a dedicated antibiotic prescription 
chart and dedicated antibiotic stewardship ward rounds, which 
alternated weekly between two medical wards. Rounds were led 
by an infectious diseases subspecialist, and the team included 
medical microbiologists, pharmacists, infection prevention control 
practitioners and the junior clinicians directly responsible for the 
patients’ care. Each patient on a ward was reviewed individually 
and a pertinent history was given regarding antibiotic prescribing 
and the use of intravenous cannulas and urinary catheters. Each 
case was then discussed, an action plan agreed upon and education 
around AS imparted.
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Background. Overuse of antibiotics has driven global bacterial resistance to the extent that we have entered a post-antibiotic era, where 
infections that were once easily treatable are now becoming untreatable. Efforts to control consumption have focused on antibiotic 
stewardship programmes (ASPs), aimed at optimising use.
Objective. To report antibiotic consumption and cost over 4 years from a public hospital ASP in South Africa (SA).
Methods. A comprehensive ASP comprising online education, a dedicated antibiotic prescription chart and weekly dedicated ward rounds 
was introduced at Groote Schuur Hospital, Cape Town, in 2012. Electronic records were used to collect data on volume and cost of 
antibiotics and related laboratory tests, and to determine inpatient mortality and 30-day readmission rates. These data were compared with 
a control period before the intervention.
Results. Total antibiotic consumption fell from 1 046 defined daily doses/1 000 patient days in 2011 (control period) to 868 by 2013 
and remained at similar levels for the next 2 years. This was driven by reductions in intravenous antibiotic use, particularly ceftriaxone. 
Inflation-adjusted cost savings on antibiotics were ZAR3.2 million over 4 years. Laboratory tests increased over the same period with a total 
increased cost of ZAR0.4 million. There was no significant change in mortality or 30-day readmission rates.
Conclusions. The effects of a comprehensive ASP on medical inpatients at a public sector hospital in SA were durable over 4 years, leading 
to a reduction in total antibiotic consumption without adverse effect. When increased laboratory costs were offset there was a net cost saving 
of ZAR2.8 million.
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There have been important changes to the 
ASP since 2012. Ward rounds have been 
extended to cover all four of the internal 
medicine wards on a weekly basis, and 
as institutional knowledge has increased, 
ward rounds have been able to focus on 
smaller numbers of patients with complex 
problems rather than including every 
patient on all four wards. Initially, certain 
anti biotics were restricted and required 
release by a microbiologist or infectious 
diseases physician; these were intravenous 
ciprofloxacin, carbapenems, piperacillin-
tazobactam, colistin, tigecyc line, aztreonam, 
linezolid and vancomycin. In March 2013 the 
restrictions for intra venous ciprofloxacin, 
ertapenem, pipera cillin-tazobactam and 
vanco mycin were lifted, although release 
by the consultant responsible for the patient 
was still required.
Antibiotic consumption
Electronic pharmacy dispensing records 
were used to calculate consumption and 
cost of antibiotics, with oral and parenteral 
formulations of the same antibiotic treated 
separately. Antibiotics that had been used 
to treat mycobacterial, parasitic and fungal 
infections, including co-trimoxazole,  were 
excluded. Antibiotic use during the inter-
vention period (1 January 2012 - 31 Dec-
ember 2015) was compared with that 
during the control period (1 January 
2011 - 31 December 2011). Con sumption 
of antibiotics was converted into defined 
daily doses (DDDs) according to the World 
Health Organization standard. All costs 
were adjusted for inflation using the SA 
Consumer Price Index (CPI) (December 
2012 = 100).
Laboratory tests
The number and costs of blood culture (BC), 
full blood count (FBC), white blood cell 
count differential (WBC), C-reactive protein 
(CRP) and procalcitonin (PCT) requests 
were calculated from the National Health 
Laboratory Service database.
Patient data
Data on inpatient mortality and hospital-
wide, all-cause readmission to Groote 
Schuur Hospital within 30 days of discharge 
were obtained from the hospital electronic 
admissions database (Clinicom).
Ethics
The study was approved by the Human 
Research Ethics Committee of the Faculty 
of Health Sciences, University of Cape Town 
(ref. no. 004/2012).
Results
Change in antibiotic consumption
The total consumption of antibiotics on the 
four wards in 2011 was 1 046 DDD/1 000 
patient bed days. There was no change overall 
in 2012, but in each of the subsequent years 
there was a decrease of approximately 18% 
compared with 2011. This reduction was 
driven mainly by decrease in intravenous 
antibiotic consumption, which fell by 25 - 
30% in the years 2013 - 2015, compared 
with 2011. By contrast, there was very little 
Table 1. Antibiotic use on four medical wards over 5 years (2012 - 2015 and the control period 2011)
Year
All antibiotics, 
DDDs/1 000 
patient bed days
Change in all 
antibiotics since 
2011, %
Intravenous 
antibiotics, DDDs/ 
1 000 patient bed 
days
Change in 
intravenous 
antibiotics since 
2011, %
Oral antibiotics, 
DDDs/1 000 
patient bed days
Change in oral 
antibiotics since 
2011, %
2011 1 046 592 454
2012 1 061 +1.5 591 –0.1 470 +3.5
2013 868 –17.1 411 –31 457 +0.7
2014 843 –19.4 409 –31 434 –4.4
2015 864 –17.4 443 –25 421 –7.3
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Fig. 1. Changes in use of intravenous antibiotics on four medical wards over 5 years (2012 - 2015 and 
the control period 2011).
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Fig. 2. Direct cost of antibiotics used on four medical wards over 5 years (2012 - 2015 and the control 
period 2011). Costs adjusted for inflation using SA CPI: December 2012 = 100.
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difference in consumption of oral antibiotics over this period 
(Table  1). The change in consumption of individual intravenous 
antibiotics is shown in Fig. 1. There were consistent reductions in most 
antibiotics, notably a 54% reduction in use of ceftriaxone between 
2011 and 2015. An exception was cloxacillin, which increased by 56% 
over the same period, coinciding with increased education around 
the correct recommended dose.
Change in antibiotic cost
The inflation-adjusted cost of antibiotics was ZAR2 191 594 in 
2011 and lower for each of the subsequent years. By 2015, inflation-
adjusted cost was 46% lower than in 2011 (Table 2, Fig. 2). The total 
saved over the 4 years was ZAR3 263 340.
Laboratory tests
Fig. 3 shows the trend in use of infection-related laboratory tests over 
the study period. The number of requests for FBCs and BCs rose from 
162 to 204, and 24.7 to 30.9 per 1 000 patient bed days, respectively. 
PCT requests peaked in 2012 shortly after their introduction and 
subsequently declined year on year. The inflation-adjusted cost of 
these tests was ZAR504 333 in 2011, peaking at ZAR721 280 in 2012 
(43% above baseline), before falling to <15% above baseline for the 
subsequent 3 years (Table 3). The total extra spending on tests over 
4 years was ZAR401 903.
Inpatient mortality and readmission rates
The total number of patient days increased over the duration of the 
study from <39 000 in 2011 to almost 43 000 in 2015. During this 
time the mortality rate remained constant at 0.12 deaths/admission 
and only non-significant changes in the readmission rate were 
observed (Table 4).
Discussion
This study confirms that the introduction of an ASP into a public 
sector hospital in SA is feasible, and can produce a sustained reduction 
in antibiotic consumption without compromising patient care. As 
there was no significant change in oral antibiotic consumption over 
the intervention period, our results suggest that the main driver 
of inappropriate antibiotic use in our hospital was unnecessary 
intravenous antibiotics. Our results showing ~18% reduction in 
antibiotic use are consistent with a systematic review of change in 
antibiotic prescribing for controlled before-after studies where the 
median reduction in antibiotic usage was 17.7%.[13]
Our ASP realised a >40% reduction in direct antibiotic costs from the 
second year onwards, and a much smaller rise in the cost of laboratory 
tests despite an 8.6% increase in patient bed days from 2011 to 2015. 
It is noteworthy that the 19.6% reduction in antibiotic use reported in 
our pilot study intervention was maintained as the ASP was rolled out 
to all four wards. Total cost savings are likely to be much higher than 
the direct costs of the antibiotics themselves when the reduction in 
use of consumable items such as intravenous giving sets and cannulas, 
as well as savings in nurses’ time, are taken into account. Although 
we have not been able to demonstrate reductions in complications 
such as peripheral line infections and Clostridium difficile-associated 
diarrhoea (CDAD), these are strongly associated with reductions in use 
of intravenous therapy and broad-spectrum antibiotics.
The ASP is a multifaceted programme and it is therefore not 
possible to determine which of the individual features has been most 
successful. Our impression however has been that dedicated weekly 
ward rounds with AS ‘champions’, where fundamental principles of 
stewardship are reinforced, have led to an improved knowledge base, 
particularly in the registrar grade of doctors. Registrars rotate through 
the general internal medicine wards on a 3-monthly basis and many 
have returned for more than one rotation, which reinforces their 
learning. Interestingly, the medical consultants have not attended 
rounds despite invitation to do so, which has created an unexpected 
tension in that junior doctors are often better educated than their 
seniors when it comes to optimal antibiotic prescribing. With the 
continued hierarchical approach to medicine in SA, this is creating a 
barrier to patients receiving optimal antibiotic management.
Table 2. Direct cost of antibiotics used on four medical 
wards over 5 years (2012 - 2015 and the control period 2011)
Year Cost* (ZAR)
Decrease from 
2011* (ZAR)
Decrease 
from 2011, %
2011 2 191 594
2012 1 800 808 390 786 18
2013 1 277 481 914 113 42
2014 1 236 797 954 796 44
2015 1 187 942 1 003 652 46
*Costs adjusted for inflation using the SA CPI: December 2012 = 100.
Table 3. Cost of infection-related blood tests (BC, FBC, 
WBC, CRP and PCT) requested from four medical wards 
over 5 years (2012 - 2015 and the control period 2011)
Year Costs* (ZAR)
Increase from 
2011* (ZAR)
Increase from 
2011, %
2011 504 333
2012 721 280 216 947 43
2013 575 875 71 542 14
2014 546 936 42 603 8
2015 575 144 70 811 14
*Costs adjusted for inflation using the SA CPI: December 2012 = 100.
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Fig. 3. Numbers of requests for infection-related investigations from four 
medical wards over 5 years  (2012 - 2015 and the control period 2011).
Table 4. Patient outcomes on four medical wards over 5 years
Year
Inpatient 
days
Average 
length of 
stay (days)
Mortality 
rate, deaths/
admission
Readmissions, 
%
2011 39 578 7.4 0.12 9.6
2012 37 033 7.3 0.12 10.4
2013 41 428 6.5 0.12 11.1
2014 42 621 6.8 0.12 10.3
2015 42 995 7.6 0.12 11.0
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Our study has a number of limitations. Owing to its observational 
design we were unable to control for any confounding variables that 
may affect antibiotic prescribing. We are also unable to determine the 
effects of our intervention on important patient-orientated outcomes 
such as rates of CDAD or multidrug-resistant Gram-negative 
bloodstream infections. However, it has previously been shown 
that reduction in antibiotic use leads to reductions in resistance 
rates[15] and it is reasonable to assume that our intervention has had 
an effect in this area. A further limitation is the lack of potential 
reproducibility of the intervention in hospitals across SA and in other 
resource-limited settings. As the O’Neill report[12] has highlighted, 
investment in persons practising infection-related specialties in 
the workplace has been poor and SA is no exception, with a severe 
shortage in infectious diseases specialists and microbiologists in 
particular. However, we would contend that AS champions who 
can create change and optimise antibiotic use in hospitals do not 
have to be limited to these role-players. To this end, two national 
training centres for AS have been funded, and the first 5-day train-
the-trainer course was held at Groote Schuur Hospital in July 2016. 
The express objective of this initiative is to address inequity of 
access to healthcare practitioners with expertise in AS in provinces 
that have limited or no infection specialists and no ASPs currently 
in place. The first course hosted trainees from six hospitals in the 
Eastern Cape, and provided practical teaching on how to set up an 
ASP and perform AS rounds. Follow-up visits to each hospital will 
help mentor teams in the development of their ASPs. The recent 
demonstration that a non-specialist pharmacist intervention in 
Netcare hospitals across SA was able to achieve similar reductions 
in consumption highlights the opportunity to develop a number of 
different ASP models within SA that could be tailored to different 
settings.[16] ASPs centred around nurses have yet to be trialled, but 
the success of task-shifting antiretroviral treatment management 
from doctors to nurses in the STRETCH model,[17] suggests that this 
cadre of healthcare professional could be an important addition to 
stewardship programmes within and outside SA.
Conclusions
The cost savings realised as a result of our ASP should be of interest 
to hospital, provincial and national health managers, as well as key 
operators in the private sector, including medical aids. ASPs can not 
only fund themselves, but potentially be a source of revenue to put 
back into infection prevention and quality improvement programmes 
improving patient safety related to infection. Internationally, ASPs 
are recognised as reducing length of hospital stay, affecting already 
overburdened health institutions.[18]
Future work in this area will focus on the reproducibility of our 
intervention in other healthcare settings, as a result of the national 
training programme. Additionally, further research is needed on 
combining different models of ASP in low-resource settings.
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